After randomization of 312 patients in remission , patients whose dose had been increased to 20mg escitalopram after 2 weeks of open-label treatment had a high escitalopram relapse rate ( 16.7 % ) and a placebo relapse rate of 32.5 % with a hazard ratio ( HR ) of 2.2 , whereas patients titrated to 20mg escitalopram at Weeks 4 or 6 had a high placebo relapse rate ( 41.2 % ) and an escitalopram relapse rate of 5.7 % with a HR = 8.9 .